Please fill out the form below and we will gladly respond as soon as possible.
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual growth rate (CAGR) of approximately 7.9% from 2026 to 2033. While market reports focus on financial trends and market size, they also reflect increasing investment in rare cancer research, drug development pipelines, and emerging therapies. […]
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have faced a structural disadvantage. Fewer treatment options. Fewer clinical trials. Less research funding. Now a new law in the United Kingdom aims to change that. The Rare Cancers Bill, introduced by Dr Scott Arthur MP, […]
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for its second community webinar—an evening focused on progress, partnership, and hope. The full webinar recording is available to watch below: The webinar was moderated by Nathan Imperiale, Chairman of the Board, and featured: Highlights Foundation […]
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
We are thrilled to announce a significant milestone for the Synovial Sarcoma Registry and Biospecimen Repository, as we proudly welcome our 100th registrant. This achievement signifies the growing commitment to advancing research and improving treatment options for patients with synovial sarcoma. The registry serves as a pivotal resource, collecting invaluable data and biospecimens from patients […]
Current Patient to Drive Relationships and Support for the Synovial Sarcoma Community [Philadelphia, PA] – 12/12/25 – The Synovial Sarcoma Foundation (SSF) is thrilled to announce the appointment of Julie Kramer as our new Community Engagement & Partnerships Manager. With a wealth of experience in advocacy and nonprofit communications, and as a survivor of synovial […]
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics. Synovial sarcoma primarily develops in soft tissues such as muscles […]
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a […]